Secretary’s Report for 17th Meeting, 10 November 2009

A. Progress on minuted actions arising during the 16th Meeting, 12th June 2009

<table>
<thead>
<tr>
<th>Min. Ref.</th>
<th>Action</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.18</td>
<td>The Chairman to seek clarity from HSE on the future role of ACTS and WATCH and to provide a clear position on this matter at the Autumn WATCH meeting.</td>
<td>Verbal feedback to be provided on 10th November 2009</td>
</tr>
</tbody>
</table>

B. Updates on other activities

For information:
16th meeting, June 2009, Item 6

The potential for WATCH contribution to consultation processes launched by others – examples to consider

Members will recall that under item 6 at the June 2009 meeting, members discussed the potential for WATCH contribution to consultation processes, using the specific example of “A consultation on Gamma Butyrolactone (GBL)” that was being conducted by the Advisory Council on the Misuse of Drugs (ACMD).

The general feeling amongst members was that since the ACMD, also a government advisory council were addressing this issue, that WATCH should not duplicate the work of other groups within whose remit specific issues lie and therefore it was not appropriate for WATCH to respond to the ACMD consultation on the control of GBL, or issues such as this, unless HSE is approached directly.

Members may have read in the news that in August the Home Office concluded that GBL should be classified as a “category C” substance which has implications to the sale of GBL to the general public (http://news.bbc.co.uk/1/hi/uk/8218688.stm).